APONTIS PHARMA reports accelerated growth in first half of 2021 – Single Pill revenues +83% to EUR 14.0 million

Monheim am Rhein, 28 July 2021. APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specialising in Single Pills in the German market, achieved revenue growth of 36% to EUR 24.0 million in the first half of 2021 on the basis of preliminary figures. Growth accelerated over the course of the six-month period, in particular due to the strong demand for Single Pills, including the proprietary new developments Atorimib® (cholesterol-lowering agent) and Tonotec® HCT (antihypertensive agent). In view of the market dynamics in the second half of the year due to industry and seasonal factors, the Management Board confirms the forecast for the full year 2021.
Single Pill revenues increased significantly by 83% to EUR 14.0 million in the first half of 2021 and accounted for 58% of APONTIS PHARMA’s total revenues (H1 2020: 43%). Both the growth in revenues and the share of Single Pills thus exceeded management’s expectations. Earnings before interest, taxes, depreciation and amortisation (adjusted EBITDA), which are mainly adjusted for the costs of the IPO, rose by EUR 4.3 million to EUR 2.8 million at Group level according to preliminary calculations (H1 2020: negative result). With an adjusted EBITDA margin of 11.8%, APONTIS PHARMA is within the forecast for the current financial year communicated in connection with the IPO and is well on the way to achieving the medium-term target of around 30%.
For financial year 2021, the Management Board continues to expect revenues in the region of EUR 48.5 million and adjusted EBITDA of EUR 5.5 million.
Karlheinz Gast, CEO of APONTIS PHARMA AG: “In a successful first half of the year, we managed to expand our unique positioning, revenue growth and market leadership in the area of Single Pills. APONTIS PHARMA is thus directly on track to meet the forecast for the current financial year 2021 communicated in connection with the IPO. Demand for our Single Pills for improved and practical treatment of chronically ill patients exceeded our expectations. At the same time, the general market development in the first half of 2021 was characterised by a shortage of care for chronically ill patients as a result of the COVID-19-related lockdowns and strong demand for vaccinations. The progress we made in marketing our own product portfolio, including receiving the recommendation of AXA Health Insurance for Single Pill therapy to treat hypertension, was all the more encouraging for us as ‘The Single Pill Company.’ As the market leader in Single Pills with a focus on cardiovascular disease, we expect the momentum of increasing demand for Single Pill therapies to accelerate further in the second half of 2021 due to the return to normal, and thus better access to medical care.”
Preliminary, unaudited Group figures H1 2021
in EUR million H1 2021 H1 2020 ∆
Single Pill revenues 14.0 7.7 83.2%

Total revenues 24.0 17.7 35.9%
EBITDA adjusted 2.8 -1.4 n/a
EBITDA margin adjusted (in %) 11.8 -8.1 n/a

APONTIS PHARMA AG’s full 2021 half-year report will be available on the company’s website at ir.apontis-pharma.de as of 11 August 2021.

CEO Karlheinz Gast and CPO Thomas Milz will explain the results of the first half of 2021 in a webcast presentation on 11 August 2021 at 14.00 CEST. The presentation will be held in English.
Please register in time to participate at:
APONTIS PHARMA Half Year Report 2021 – Webcast/Teleconference.
The accompanying presentation will also be available on the company’s website prior to the start.
APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in Germany. Single Pills combine two to three generic active ingredients in a single dosage form. APONTIS PHARMA develops, promotes and sells a broad portfolio of Single Pills and other pharmaceutical products, with a special focus on cardiovascular diseases. Since 2013, APONTIS successfully launched several Single Pill products alone for cardiovascular indications such as hypertension, hyperlipidemia and secondary prevention. With its headquarters in Monheim am Rhein, APONTIS PHARMA is located in one of Europe’s leading pharmaceutical and chemical region. From here, the company maintains a broad network with research-based pharmaceutical companies and a customer target group of approx. 23,000 physicians in Germany. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de.
Investor Relations
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. 10
40789 Monheim am Rhein
CROSS ALLIANCE communication GmbH
Sven Pauly
Sara Pinto
T: +49 89 125 09 0330

Linda Lenz

"Creativity and perfection are not mutually exclusive, but complementary."

IR Consultant at CROSS ALLIANCE since 2021.
Linda Lenz’s core competencies are public and influencer relations as well as project management.
With a a M.Sc. degree in Strategic Communication and PR and a B.A. in English Studies and Communication and Media Studies, she is fully committed to her clients because she always insists on doing the job right.
4 years of experience in Public Relations and Influencer Relations expertise in the Automotive and Energy Special Supporter ESG industries.

Jens Jüttner

"Designing a customised communication strategy for clients is what drives me. Their success is my reward."

Jens Jüttner has extensive experience in news and business journalism across all presentation formats and channels. As an investor relations consultant, he devotes his energies to the regular communications of listed companies and also provides support with their media relations activities.

Senior Consultant at CROSS ALLIANCE since 2018
BA in Journalism / Banking Officer
Five years as a member of the editorial team of business and investor magazine FOCUS-MONEY
Three years as Head of Department for “Week”
Extensive experience in writing advertorials
Shortlisted for the Alternative Media Prize 2013
Social Media Manager (Chambers of Industry and Commerce) – final project: Development of a hybrid social media campaign for LinkedIn and Twitter for an IR and media agency

T: +49 89 125 09 03 32

Markus Horntrich

"My maxim to ensure optimum performance on all your communications issues: Get up early, give it your all and work hard."

Markus Horntrich is a stock market enthusiast and, as a former editor-in-chief, has extensive experience in financial journalism and a broad network, which he uses as a basis for all aspects of PR/IR communication.

Economics graduate

Self-employed PR/IR consultant and Senior Consultant at CROSS ALLIANCE
19 years at investor magazine DER AKTIONÄR
8 years as editor-in-chief at DER AKTIONÄR

T: +49 89 125 09 03 30
M: +49 170 321 42 26

Michael Lang

"As a former editor-in-chief and full-blooded journalist, a matter particularly close to my heart is ensuring that our clients get noticed in just the right way in the media."

As an experienced business journalist, Michael Lang uses his extensive network in the financial community to give clients the best media relations.

Partner at CROSS ALLIANCE since 2013
Self-employed professional in investor relations since 2010
Head of IR at IBS AG (Prime Standard) for four years
Ten years as a member of the editorial team of financial magazine DER AKTIONÄR (“2010 award for investor magazine of the year”), acting as editor-in-chief and deputy editor-in-chief, in both positions for three years
15 years of experience in financial journalism
Degree in Business Mathematics, Bayreuth University

T: +49 89 125 09 03 34

Susan Hoffmeister

"I support every company with communication just as I do my own. That's my biggest motivation."

Managing Partner Susan Hoffmeister supports listed companies with their investor relations.

Founder & Managing Director of CROSS ALLIANCE communication GmbH
Degree in Business Administration, BA in Finance & Accounting, MBA
Self-employed entrepreneur in investor relations since 2006
Deutsche Börse qualified Supervisory Board member since 2017
Member of the Supervisory Board of LEHNER INVESTMENTS AG
Head of Corporate Communications at Siemens London for five years
Head of IR at various listed companies in the software and IT industry for six years

Extensive IPO experience
T: +49 89 125 09 03 33

Sara Pinto

"My motto is 'Create value through communication'. My international professional background helps me to achieve this. I work with clients to get them the best results."

As an investor relations expert and member of the Cross Alliance team, Sara Pinto places particular emphasis on providing her clients with in-depth consultations and on strategic communication. Her specialist area is sustainability.

Consultant at CROSS ALLIANCE since 2019

MA in Business Administration & Management
Five years as Market Research Manager at FOCUS-MONEY

Extensive experience in B2B sales
Expert in CSR and ESG – contact person for sustainability strategy development, implementation of ESG criteria in corporate communications, and sustainability reporting
Language proficiency: Italian (mother tongue), German, English, Spanish

T: +49 89 125 09 03 35

Sven Pauly

"I develop innovative concepts for our clients, which actively contributes to their success."

Investor relations consultant Sven Pauly has extensive experience in TV news production, and specialises in reporting and regular communications for listed companies.

Senior Consultant at CROSS ALLIANCE since 2016
MA in Corporate Communications/PR
Consultant for investor relations and corporate communications
Extensive experience in capital market consultation
Has held roles in designated sponsoring and public affairs
Over ten years of experience in TV news production

T: +49 89 125 09 03 31